Interferons as biomarkers and effectors: Lessons learned from animal models

Biomarkers in Medicine

Volumn 6, Issue 2, 2012, Pages 159-176

  Berry, Cassandra M ^b   Hertzog, Paul J ^a   Mangan, Niamh E ^a  

^a MONASH UNIVERSITY   (Australia)

^b MURDOCH UNIVERSITY   (Australia)

Author keywords

autoimmune disease; biomarker; innate immunity; interferon stimulated gene; signaling pathway; therapy; type I interferon response; viral infection

Indexed keywords

ALPHA INTERFERON; ALPHA INTERFERON RECEPTOR; ALPHA1 INTERFERON; ALPHA2 INTERFERON; ALPHA4 INTERFERON; ALPHA5 INTERFERON; BETA INTERFERON; BETA INTERFERON RECEPTOR; BIOLOGICAL MARKER; CD20 ANTIBODY; CPG OLIGODEOXYNUCLEOTIDE; DNA VACCINE; GAMMA INTERFERON; HERPES SIMPLEX VACCINE; INFLUENZA VACCINE; INTERFERON; INTERLEUKIN 10 RECEPTOR; INTERLEUKIN 28; INTERLEUKIN 29; JANUS KINASE; RITUXIMAB; STAT PROTEIN; SUPPRESSOR OF CYTOKINE SIGNALING 1; TOLL LIKE RECEPTOR 2; TOLL LIKE RECEPTOR 3; TOLL LIKE RECEPTOR 4; TOLL LIKE RECEPTOR 9; UNCLASSIFIED DRUG;

2 5OAS GENE; AUTOIMMUNE DISEASE; CD80 GENE; CD86 GENE; CLINICAL RESEARCH; CYTOKINE PRODUCTION; CYTOMEGALOVIRUS; EXPERIMENTAL MODEL; GENE; GENE INACTIVATION; GENETIC TRANSCRIPTION; HERPES SIMPLEX; HERPES SIMPLEX VIRUS 1; HERPES SIMPLEX VIRUS 2; HUMAN; IMMUNE RESPONSE; INFECTION RESISTANCE; INFLUENZA A; INOS GENE; IRF7 GENE; ISG56 GENE; MHC GENE; MULTIPLE SCLEROSIS; MXA GENE; NONHUMAN; PATHOGENESIS; PKR GENE; PROGNOSIS; PROTEIN FAMILY; PROTEIN FUNCTION; PROTEIN INDUCTION; PROTEIN PHOSPHORYLATION; REVIEW; RNASEL GENE; SIGNAL TRANSDUCTION; SYSTEMIC LUPUS ERYTHEMATOSUS; VIRUS INFECTION; VIRUS MYOCARDITIS;

ANIMALS; AUTOIMMUNE DISEASES; BIOLOGICAL MARKERS; DISEASE MODELS, ANIMAL; HUMANS; INTERFERONS; VIRUS DISEASES;

ANIMALIA;

EID: 84859061747     PISSN: 17520363     EISSN: 17520371     Source Type: Journal    
DOI: 10.2217/bmm.12.10     Document Type: Review

References (164)

1. Isaacs A, Lindenmann J. Virus interference. I. The interferon. Proc. R. Soc. Lond. B Biol. Sci. 147, 258-267 (1957).
2. Hertzog P, Forster S, Samarajiwa S. Systems biology of interferon responses. J. Interferon Cytokine Res. 31(1), 5-11 (2011).
3. Brandt ER, Linnane AW, Devenish R. Expression of IFN A genes in subpopulations of peripheral blood cells. Br. J. Haematol. 86(4), 717-725 (1994).
4. Julkunen I, Linnavuori K, Hovi T. Sensitive interferon assay based on immunoenzymatic quantification of viral antigen synthesis. J. Virol. Methods 15(2), 85-91 (1982).
5. Samarajiwa SA, Forster S, Auchetti K, Hertzog PJ. Interferome: the database of interferon regulated genes. Nucleic Acids Res. 37, D852-D857 (2009).
6. Durfee LA, Huibregtse JM. Identification and validation of ISG15 target proteins. Subcell. Biochem. 54, 228-237 (2010).
7. Cahilly LA, George D, Daugherty BL, Pestka S. Subchromosomal localization of mouse IFN-alpha genes by in situ hybridisation. J. Interferon Res. 5(3), 391-395 (1985).
8. Kontsek P, Karayianni-Vasconcelos G, Kontsekova E. The human interferon system: characterization and classification after discovery of novel members. Acta Virol. 47(4), 201-215 (2003).
9. Hardy MP, Owczarek CM, Jermiin LS, Ejdeback M, Hertzog PJ. The soluble murine type I interferon receptor Ifnar-2 is present in serum, is independently regulated, and has both agonistic and antagonistic properties. Blood 97, 473-482 (2001).
10. Hardy MP, Owczarek CM, Jermiin LS, Ejdeback M, Hertzog PJ. Characterization of the type I interferon locus and identification of novel genes. Genomics 84, 331-345 (2004).
11. Zwarthoff EC, Mooren AT, Trapman J. Organization, structure and expression of murine interferon alpha genes. Nucleic Acids Res. 13, 791-804 (1985).
12. Kotenko SV, Gallagher G, Baurin VV et al. IFN-lambdas mediate antiviral protection through a distinct class II cytokine receptor complex. Nat. Immunol. 4(1), 69-77 (2003).
13. Sheppard P, Kindsvogel W, Xu W et al. IL-28, IL-29 and their class II cytokine receptor IL-28R. Nat. Immunol. 4, 63-68 (2003).
14. Donelly RP, Kotenko SV. Interferon-lambda: a new addition to an old family. J. Interferon Cytokine Res. 30(8), 555-564 (2010).
15. Asselin-Paturel C, Trinchieri G. Production of type I interferons: plasmacytoid dendritic cells and beyond. J. Exp. Med. 202(4), 461-465 (2005).
16. Coccia EM, Severa M, Giacomini E et al. Viral infection and Toll-like receptor agonists induce a differential expression of type I and lambda interferons in human plasmacytoid and monocyte-derived dendritic cells. Eur. J. Immunol. 34(3), 796-805 (2004).
17. Noppert SJ, Fitzgerald KA, Hertzog PJ. The role of type I interferons in TLR responses. Immunol. Cell Biol. 85, 446-457 (2007).
18. Pestka S. The interferons: 50 years after their discovery, there is much more to learn. J. Biol. Chem. 282(28), 20047-20052 (2007).
19. Baig E, Fish EN. Distinct signature type I interferon responses are determined by the infecting virus and the target cell. Antivir. Ther. 13, 409-422 (2008).
20. De Weerd NA, Samarajiwa SA, Hertzog PJ. Type I interferon receptors: biochemistry and biological functions. J. Biol. Chem. 282, 20053-20057 (2007).
21. Krause CD, Pestka S. Historical developments in the research of interferon receptors. Cytokine Growth Factor Rev. 18, 473-482 (2007).
22. Moraga I, Harari D, Schreiber G et al. Receptor density is key to the alpha2/beta interferon differential activities. Mol. Cell Biol. 29(17), 4778-4787 (2009).
23. Jaitin DA, Roisman LC, Jaks E et al. Inquiring into the differential action of interferons (IFNs): an IFN-alpha 2 mutant with enhanced affinity to IFNAR1 is functionally similar to IFN-beta. Mol. Cell Biol. 26(5), 1888-1897 (2006).
24. Fujiwara D, Hino K, Yamaguchi Y et al. Type I interferon receptor and response to interferon therapy in chronic hepatitis C patients: a prospective study. J. Viral Hepat. 11(2), 136-140 (2004).
25. Sommereyns C, Paul S, Staeheli P, Michiels T. IFN-lambda (IFN-lambda) is expressed in a tissue-dependent fashion and primarily acts on epithelial cells in vivo. PLoS Pathog. 4, E1000017 (2008).
26. Marukian S, Andrus L, Sheahan TP et al. Hepatitis C virus induces interferon-l and interferon stimulated genes in primary liver cultures. Hepatology 54(56), 1913-1923 (2011).
27. Der SD, Zhou A, Williams BR, Silverman RH. Identification of genes differentially regulated by interferon alpha, beta, or gamma using oligonucleotide arrays. Proc. Natl Acad. Sci. USA 95(26), 15623-15628 (1998).
28. Stark GR. How cells respond to interferons revisited: from early history to current complexity. Cytokine Growth Factor Rev. 18(5-6), 419-423 (2007).
29. Cull VS, Tilbrook PT, Bartlett EJ, Brekalo NL, James CM. Type I interferon differential prognosis in the treatment of erythroleukemia: specificity of STAT activation. Blood 101, 2727-2735 (2003).
30. Stark GR, Wang Y, Lu T. Lysine methylation of promoter-bound transcription factors and releVance to cancer. Cell Res. 21(3), 375-380 (2011).
31. Stanton GJ, Weigent DA, Fleischmann WR Jr, Dianzani F, Baron S. Interferon review. Invest. Radiol. 22(3), 259-273 (1987).
32. Hertzog PJ, Mansell A, Van Driel IR, Hartland EL. Sculpting the immune response to infection. Nat. Immunol. 12(7), 579-582 (2011).
33. Borden EC, Williams BR. Interferon-stimulated genes and their protein products: what and how? J. Interferon Cytokine Res. 32(1), 1-4 (2011).
34. Schoggins JW, Wilson SJ, Panis M et al. A diverse range of gene products are effectors of the type I interferon antiviral response. Nature 472(7344), 482-485 (2011).
35. Lavoie TB, Kalie E, Crisafulli-Cabatu S et al. Binding and activity of all human alpha interferon subtypes. Cytokine 56(2), 282-289 (2011
36. Heim MH. The Jak-STAT pathway: cytokine signalling from the receptor to the nucleus. J. Recept. Signal Transduct. Res. 19(1-4), 75-120 (1999).
37. Lau AS, Williams BR. The role of interferon and tumor necrosis factor in the pathogenesis of AIDS. J. Exp. Pathol. 5(3), 111-122 (1990).
38. Wormald S, Hilton DJ. Inhibitors of cytokine signal transduction. J. Biol. Chem. 279(2), 821-824 (2004).
39. Katze MG, He Y, Gale M Jr. Viruses and interferon: a fight for supremacy. Nat. Rev. Immunol. 2(9), 675-687 (2002).
40. Lehmann C, Taubert D, Jung N et al. Preferrential upregulation of interferon-alpha subtype 2 expression in HIV-1 patients. AIDS Res. Hum. Retroviruses 25, 577-581 (2009).
41. Pfeffer LM, Dinarello CA, Herberman RB et al. Biological properties of recombinant alpha-interferons: 40th anniversary of the discovery of interferons. Cancer Res. 58(12), 2489-2499 (1998).
42. Hwang SY, Hertzog PJ, Holland KA et al. A null mutation in the gene encoding a type I interferon receptor component eliminates antiproliferaive and antiviral responses to interferons alpha and beta and alters macrophage responses. Proc. Natl Acad. Sci. USA 92(24), 11284-11288 (1995).
43. Kohlmeier JE, Cookenham T, Roberts AD et al. Type I interferons regulate cytolytic activity of memory CD8+ T cells in the lung airways during respiratory virus challenge. Immunity 33(1), 96-105 (2010).
44. Seo SU, Kwon HJ, Ko HJ et al. Type I interferon signaling regulates Ly6Chi monocytes and neutrophils during acute viral pneumonia in mice. PLoS Pathog. 7(2), E1001304 (2011).
45. Deonarain R, Cerullo D, Fuse K et al. Protective role for interferon-beta in coxsackievirus B3 infection. Circulation 110(23), 3540-3545 (2004).
46. Hayman A, Comely S, Lackenby A et al. Variation in the ability of human influenza A viruses to induce and inhibit the IFN-beta pathway. Virology 347, 52-64 (2006).
47. Mancuso G, Midiri A, Biondo Cet al. Type I IFN signaling is crucial for host resistance against different species of pathogenic bacteria. J. Immunol. 178(5), 3126-3133 (2007).
48. Galligan CL, Pennell LM, Murooka TT et al. Interferon-beta is a key regulator of proinflammatory events in experimental autoimmune encephalomyelitis. Mult. Scler. 16(12), 1458-1473 (2010).
49. Li S, Wang L, Berman M et al. Mapping a dynamic innate immunity protein interaction network regulating type I interferon production. Immunity 35(3), 426-440 (2011).
50. Octaviani CP, Ozawa M, Yamada S et al. High level of genetic compatibility between swine-origin H1N1 and highly pathogenic avian H5N1 influenza viruses. J. Virol. 84(20), 10918-10922 (2010).
51. Chen LM, Blixt O, Stevens J et al. In vitro evolution of H5N1 avian influenza virus toward human-type receptor specificity. Virology 30(1), 36-47 (2012).
52. Burke JD, Fish EN. Antiviral strategies: the present and beyond. Curr. Mol. Pharmacol. 2(1), 32-39 (2009).
53. Durbin JE, Fernandez-Sesma A, Lee CK et al. Type I IFN modulates innate and specific antiviral immunity. J. Immunol. 164(8), 4220-4228 (2000).
54. Mordstein M, Neugebauer E, Ditt V et al. Lambda interferon renders epithelial cells of respiratory and gastrointestinal tract resistant to viral infections. J. Virol. 84(11), 5670-5677 (2010).
55. Yoo JK, Baker DP, Fish EN. Interferon-b modulates type I immunity during influenza virus infection. Antiviral Res. 88(1), 64-71 (2010).
56. Holzinger D, Jorns C, Stertz S et al. Induction of MxA gene expression by influenza A virus requires type I and type III interferon signalling. J. Virol. 81(14), 7776-7785 (2007).
57. Shinya K, Okamura T, Sueta S et al. Toll-like receptor pre-stimulation protects mice against lethal infection with highly pathogenic influenza viruses. J. Virol. 8, 97-91 (2011).
58. Szretter KJ, Gangappa S, Belser JA et al. Early control of H5N1 influenza virus replication by the type I interferon response in mice. J. Virol. 83, 5825-5834 (2009).
59. Penski N, Hartle S, Rubbenstroth D et al. Highly pathogenic avian influenza viruses do not inhibit interferon synthesis in infected chickens but can override the interferon-induced antiviral state. J. Virol. 85(15), 7730-7741 (2011).
60. Wang J, Oberley-Deegan R, Wang S et al. Differentiated human alveolar type II cells secrete antiviral IL-29 (IFN-l1) in response to influenza A infection. J. Immunol. 182, 1296-1304 (2009).
61. Wei L, Sandbulte MR, Thomas PG, Webby RJ, Homayouni R, Pfeffer LM. NFkappaB negatively regulates interferon-induced gene expression and anti-influenza activity. J. Biol. Chem. 281(17), 11678-11684 (2006).
62. Kochs G, Garcia-Sastre A, Martinez-Sobrido L. Multiple anti-interferon actions of the influenza A virus NS1 protein. J. Virol. 81, 7011-7021 (2007).
63. Jia D, Rahbar R, Chan RW et al. Influenza virus non-structural protein 1 (NS1) disrupts interferon signaling. PLoS ONE 5(11), E13927 (2010).
64. Steel J, Lowen AC, Pena L et al. Live attenuated influenza viruses containing NS1 truncations as vaccine candidates against H5N1 highly pathogenic avian influenza. J. Virol. 83, 1742-1753 (2009).
65. Haller O, Gao S, von der Malsburg A et al. Dynamin-like MxA GTPase: structural insights into oligomerization and implications for antiviral activity. J. Biol. Chem. 285(37), 28419-28424 (2010).
66. Rong Q, Alexander TS, Koski GK, Rosenthal KS. Multiple mechanisms for HSV-1 induction of interferon alpha production by peripheral blood mononuclear cells. Arch. Virol. 148(2), 329-344 (2003).
67. Rasmussen SB, Sørensen LN, Malmgaard L et al. Type I interferon production during herpes simplex virus infection is controlled by cell-type-specific viral recognition through Toll-like receptor 9, the mitochondrial antiviral signaling protein pathway, and novel recognition systems. J. Virol. 81(24), 13315-13324 (2007).
68. Rasmussen SB, Jensen SB, Nielsen C et al. Herpes simplex virus infection is sensed by both Toll-like receptors and retinoic acid-inducible gene-like receptors, which synergize to induce type I interferon production. J. Gen. Virol. 90(Pt 1), 74-78 (2009).
69. Melchjorsen J, Rintahaka J, Søby S et al. Early innate recognition of herpes simplex virus in human primary macrophages is mediated via the MDA5/MAVS-dependent and MDA5/ MAVS/RNA polymerase III-independent pathways. J. Virol. 84(21), 11350-11358 (2010).
70. Guo Y, Audry M, Ciancanelli M et al. Herpes simplex virus encephalitis in a patient with complete TLR3 deficiency: TLR3 is otherwise redundant in protective immunity. J. Exp. Med. 208(10), 2083-2098 ( 2011).
71. Sato A, Linehan MM, Iwasaki A. Dual recognition of herpes simplex viruses by TLR2 and TLR9 in dendritic cells. Proc. Natl Acad. Sci. USA 103(46), 17343-17348 (2006).
72. Lund J, Sato A, Akira S, Medzhitov R, Iwasaki A. Toll-like receptor 9-mediated recognition of Herpes simplex virus-2 by plasmacytoid dendritic cells. J. Exp. Med. 198(3), 513-520 (2003).
73. Sørensen LN, Reinert LS, Malmgaard L, Bartholdy C, Thomsen AR, Paludan SR. TLR2 and TLR9 synergistically control herpes simplex virus infection in the brain. J. Immunol. 181(12), 8604-8612 (2008
74. Shen H, Iwasaki A. A crucial role for plasmacytoid dendritic cells in antiviral protection by CpG ODN-based vaginal microbicide. J. Clin. Invest. 116(8), 2237-2243 (2006
75. Lund JM, Linehan MM, Iijima N, Iwasaki A. Cutting edge: plasmacytoid dendritic cells provide innate immune protection against mucosal viral infection in situ. J. Immunol. 177(11), 7510-7514 (2006
76. Svensson A, Bellner L, Magnusson M, Eriksson K. Role of IFN-alpha/beta signaling in the prevention of genital herpes virus type 2 infection. J. Reprod. Immunol. 74(1-2), 114-123 (2007
77. Pasieka TJ, Lu B, Leib DA. Enhanced pathogenesis of an attenuated herpes simplex virus for mice lacking Stat1. J. Virol. 82(12), 6052-6055 (2008
78. Harle P, Cull V, Agbaga M-P et al. Differential effect of murine alpha/beta interferon transgenes on antagonization of herpes simplex virus type 1 replication. J. Virol. 76, 6558-6567 (2002
79. Harle P, Cull V, Guo L, Papin J, Lawson C, Carr D. Transient transfection of mouse fibroblasts with type I interferon transgenes provides various degrees of protection against herpes simplex virus infection. Antiviral Res. 56, 39-49 (2002
80. Austin BA, James CM, Harle P, Carr DJ. Direct application of plasmid DNA containing type I interferon transgenes to vaginal mucosa inhibits HSV-2 mediated mortality. Biol. Proced. Online 8, 55-62 (2006
81. Austin BA, James C, Silverman RH, Carr DJJ. Critical role for the oligoadenylate synthetase/RNase L pathway in response to IFN-b during acute ocular herpes simplex virus type I infection. J. Immunol. 175, 1100-1106 (2005
82. Al-Khatib K, Williams BR, Silverman RH, Halford W, Carr DJ. Distinctive roles for 2',5'-oligoadenylate synthetases and double-stranded RNA-dependent protein kinase R in the in vivo antiviral effect of an adenoviral vector expressing murine IFN-beta. J. Immunol. 172, 5638-5647 (2004
83. Al-Khatib K, Williams BR, Silverman RH, Halford W, Carr DJ. The murine doublestranded RNA-dependent protein kinase PKR and the murine 2',5'-oligoadenylate synthetase-dependent RNase L are required for IFN-beta-mediated resistance against herpes simplex virus type 1 in primary trigeminal ganglion culture. Virology 313, 126-135 (2003
84. Zheng X et al. Increased severity of HSV-1 keratitis and mortality in mice lacking the 2-5A-dependent RNase L gene. Invest. Ophthalmol. Vis. Sci. 42, 120-126 (2001
85. Khabar KS et al. Effect of deficiency of the double-stranded RNA-dependent protein kinase, PKR, on antiviral resistance in the presence or absence of ribonuclease L: HSV-1 replication is particularly sensitive to deficiency of the major IFN-mediated enzymes. J. Interferon Cytokine Res. 20, 653-659 (2000
86. Leib DA, Machalek MA, Williams BR, Silverman RH, Virgin HW. Specific phenotypic restoration of an attenuated virus by knockout of a host resistance gene. Proc. Natl Acad. Sci. USA 97, 6097-6101 (2000
87. Carr DJ, Tomanek L, Silverman RH, Campbell IL, Williams BR. RNA-dependent protein kinase is required for alpha-1 interferon transgene-induced resistance to genital herpes simplex virus type 2. J. Virol. 79, 9341-9345 (2005
88. He B, Gross M, Roizman B. The gamma(1)34.5 protein of herpes simplex virus 1 complexes with protein phosphatase 1alpha to dephosphorylate the alpha subunit of the eukaryotic translation initiation factor 2 and preclude the shutoff of protein synthesis by double-stranded RNA-activated protein kinase. Proc. Natl Acad. Sci. USA 94, 843-848 (1997
89. Melroe GT, Silva L, Schaffer PA, Knipe DM. Recruitment of activated IRF-3 and CBP/ p300 to herpes simplex virus ICP0 nuclear foci: potential role in blocking IFN-beta induction. Virology 360, 305-321 (2007
90. Johnson KE, Knipe DM. Herpes simplex virus-1 infection causes the secretion of a type I interferon-antagonizing protein and inhibits signaling at or before Jak-1 activation. Virology 396, 21-29, (2010
91. Lenschow DJ, Lai C, Frias-Staheli N et al. IFN-stimulated gene 15 functions as a critical antiviral molecule against influenza, herpes, and Sindbis viruses. Proc. Natl Acad. Sci. USA 104, 1371-1376 (2007
92. Durfee LA, Lyon N, Seo K, Huibregtse JM. The ISG15 conjugation system broadly targets newly synthesized proteins: implications for the antiviral function of ISG15. Mol. Cell. 38(5), 722-732 (2010
93. Lindner HA, Lytvyn V, Qi H, Lachance P, Ziomek E, Ménard R. Selectivity in ISG15 and ubiquitin recognition by the SARS coronavirus papain-like protease. Arch. Biochem. Biophys. 466, 8-14 (2007
94. Guerra S, Caceres A, Knobeloch KP, Horak I, Esteban M. Vaccinia virus E3 protein prevents the antiviral action of ISG15. PLoS Pathog. 4, E1000096 (2008
95. Ashkar AA, Yao XD, Gill N, Sajic D, Patrick AJ, Rosenthal KL. Toll-like receptor (TLR)-3, but not TLR4, agonist protects against genital herpes infection in the absence of inflammation seen with CpG DNA. J. Infect. Dis. 190, 1841-1849 (2004
96. Harandi AM, Eriksson K, Holmgren J. A protective role of locally administered immunostimulatory CpG oligodeoxynucleotide in a mouse model of genital herpes infection. J. Virol. 77, 953-962 (2003
97. Gill N, Davies EJ, Ashkar AA. The role of Toll-like receptor ligands/agonists in protection against genital HSV-2 infection. Am. J. Reprod. Immunol. 59, 35-43 (2008
98. Shellam GR, Redwood AJ, Smith LM, Gorman S. Diseases. In: The Mouse in Biomedical Research. Vol. 2. Fox JG, Davisson MT, Quimby FW, Barthold SW, Newcomer CE, Smith AL (Eds). Elsevier, MA, USA, 1-48 (2007
99. Brand S, Beigel F, Olszak T et al. IL-28A and IL-29 mediate antiproliferative and antiviral signals in intestinal epithelial cells and murine CMV infection increases colonic IL-28A expression. Am. J. Physiol. Gastrointest. Liver Physiol. 289, G960-G968 (2005
100. Bochtler P, Kroger A, Schirmbeck R, Reimann J. Type I IFN-induced, NKT cell-mediated negative control of CD8 T cell priming by dendritic cells. J. Immunol. 181, 1633-1643 (2008
101. Degli-Esposti MA, Smyth MJ. Close encounters of different kinds: dendritic cells and NK cells take centre stage. Nat. Rev. Immunol. 5, 112-124 (2005
102. Snyder CM, Loewendorf A, Bonnett EL et al. CD4+ T cell help has an epitope-dependent impact on CD8+ T cell memory inflation during murine cytomegalovirus infection. J. Immunol. 183, 3932-3941 (2009
103. Walton SM, Wu GY, Petruff CA et al. The dynamics of mouse cytomegalovirus-specific CD4 T cell responses during acute and latent infection. J. Immunol. 181, 1128-1134 (2008
104. Miller-Kittrell M, Sparer TE. Feeling manipulated: cytomegalovirus immune manipulation. Virol. J. 6, 4-24 (2009
105. Krauss S, Kaps J, Czech N, Paulus C, Nevels M. Physical requirements and functional consequences of complex formation between the cytomegalovirus IE1 protein and human STAT2. J. Virol. 83, 12854-12870 (2009
106. Cunningham MW. Turning point in myocarditis. Circ. Res. 105, 403-405 (2009
107. See DM, Tilles JG. Viral myocarditis. Rev. Infect. Dis. 13, 951-956 (1991
108. Kuhl U, Pauschinger M, Noutsias M et al. High prevalence of viral genomes and multiple viral infections in the myocardium of adults with "idiopathic" left ventricular dysfunction. Circulation 111, 887-893 (2005).
109. Fabre A, Sheppard MN. Sudden adult death syndrome and other non-ischaemic causes of sudden cardiac death. Heart 92, 316-320 (2006).
110. Hahn EA, Hartz VL, Moon TE et al. The myocarditis treatment trial: design, methods and patients enrollment. Eur. Heart J. 16(Suppl. O), 162-167 (1995).
111. Magnani JW, Danik HJ, Dec GW Jr, DiSalvo TG. Survival in biopsy-proven myocarditis: a long-term retrospective analysis of the histopathologic, clinical, and hemodynamic predictors. Am. Heart J. 151, 463-470 (2006).
112. Hertz MI, Aurora P, Christie JD et al. Scientific registry of the International Society for Heart and Lung Transplantation: introduction to the 2010 annual reports. J. Heart Lung Transplant. 29, 1083-1088 (2010).
113. Rose NR. Myocarditis: infection versus autoimmunity. J. Clin. Immunol. 29, 730-737 (2009).
114. Blauwet LA, Cooper LT. Myocarditis. Prog. Cardiovasc. Dis. 52, 274-288 (2010).
115. Lawson CM, O'Donoghue H, Bartholomaeus WN, Reed WD. Genetic control of mouse cytomegalovirus-induced myocarditis. Immunology 69, 20-26 (1990).
116. Lenzo JC, Mansfield JP, Sivamoorthy S, Cull VS, James CM. Cytokine expression in murine cytomegalovirus-induced myocarditis: modulation with interferon-alpha therapy. Cell. Immunol. 223, 77-86 (2003).
117. Ritter JT, Tang-Feldman YJ, Lochhead GR et al. In vivo characterization of cytokine profiles and viral load during murine cytomegalovirus-induced acute myocarditis. Cardiovasc. Pathol. 19, 83-93 (2010).
118. Tang X, Liao Y, Chen Z et al. Expression of IL-1beta and TNF-alpha in MCMV myocarditis and its role. J. Huazhong Univ. Sci. Technolog. Med. Sci. 25(3), 254-256, 259 (2005).
119. Krebs P, Kurrer MO, Kremer M et al. Molecular mapping of autoimmune B cell responses in experimental myocarditis. J. Autoimmun. 28, 224-233 (2007).
120. O'Donoghue HL, Lawson CM, Reed WD. Autoantibodies to cardiac myosin in mouse cytomegalovirus myocarditis. Immunology 71, 20-28 (1990).
121. Bartlett EJ, Lenzo JC, Sivamoorthy S, Mansfield JP, Cull VS, James CM. Type I IFN-beta gene therapy suppresses cardiac CD8 T cell infiltration during autoimmune myocarditis. Immunol. Cell Biol. 82, 119-126 (2004).
122. Cull VS, Bartlett EJ, James CM. Type I interferon gene therapy protects against cytomegalovirus-induced myocarditis. Immunology 106, 428-437 (2002).
123. Cull VS, Broomfield S, Bartlett EJ, Brekalo NL, James CM. Coimmunisation with type I IFN genes enhances protective immunity against cytomegalovirus and myocarditis in gB DNA-vaccinated mice. Gene Ther. 9, 1369-1378 (2002).
124. Nie YJ, Huang XY, Wang SH. Effect of IFN-lambda2 on apoptotic protein in the myocardium in mice with viral myocarditis. Zhongguo Dang Dai Er Ke Za Zhi 11, 296-300 (2009).
125. Kemppinen AK, Kaprio J, Palotie A, Saarela J. Systematic review of genome-wide expression studies in multiple sclerosis. BMJ 1(1), E000053 (2011).
126. Sundqvist E, Sundstrom P, Linden M et al. Epstein-Barr virus and multiple sclerosis: interaction with HLA. Genes Immun. 13(1), 14-20 (2011).
127. Teige I, Treschow A, Teige A et al. IFN-beta gene deletion leads to augmented and chronic demyelinating experimental autoimmune encephalomyelitis. J. Immunol. 170(9), 4776-4784 (2003).
128. Prinz M, Schmidt H, Mildner A et al. Distinct and nonredundant in vivo functions of IFNAR on myeloid cells limit autoimmunity in the central nervous system. Immunity 28(5), 675-686 (2008).
129. Goverman JM. Immune tolerance in multiple sclerosis. Immunol. Rev. 241(1), 228-240 (2011).
130. Maier J, Kincaid C, Pagenstecher A, Campbell IL. Regulation of signal transducer and activator of transcription and suppressor of cytokine-signaling gene expression in the brain of mice with astrocyte-targeted production of interleukin-12 or experimental autoimmune encephalomyelitis. Am. J. Pathol. 160(1), 271-288 (2002).
131. Balabanov R, Strand K, Goswami R et al. Interferon-gamma-oligodendrocyte interactions in the regulation of experimental autoimmune encephalomyelitis. J. Neurosci. 27(8), 2013-2024 (2007).
132. Tanaka K, Ichiyama K, Hashimoto M et al. Loss of suppressor of cytokine signaling 1 in helper T cells leads to defective Th17 differentiation by enhancing antagonistic effects of IFN-gamma on STAT3 and Smads. J. Immunol. 180(6), 3746-3756 (2008).
133. Berard JL, Kerr BJ, Johnson HM, David S. Differential expression of SOCS1 in macrophages in relapsing-remitting and chronic EAE and its role in disease severity. Glia 58(15), 1816-1826 (2010).
134. Perry D, Sang A, Yin Y, Zheng YY, Morel L. Murine models of systemic lupus erythematosus. J. Biomed. Biotechnol. 27, 1694-1712 (2011).
135. Schmidt KN, Ouyang W. Targeting interferon-alpha: a promising approach for systemic lupus erythromatosus therapy. Lupus 13(5), 348-352 (2004).
136. Nacionales DC, Kelly-Scumpia KM, Lee PY et al. Deficiency of the type I interferon receptor protects mice from experimental lupus. Arthritis Rheum. 56(11), 3770-3783 (2007).
137. Sigurdsson S, Nordmark G, Göring HH et al. Polymorphisms in the tyrosine kinase 2 and interferon regulatory factor 5 genes are associated with systemic lupus erythematosus. Am. J. Hum. Genet. 76, 528-537 (2005).
138. Sigurdsson S, Nordmark G, Garnier S et al. A risk haplotype of STAT4 for systemic lupus erythematosus is over-expressed, correlates with anti-dsDNA and shows additive effects with two risk alleles of IRF5. Hum. Mol. Genet. 17, 2868-2876 (2008).
139. Cunninghame Graham DS, Morris DL et al. Association of NCF2, IKZF1, IRF8, IFIH1, and TYK2 with systemic lupus erythematosus. PLoS Genet. 7(10), E1002341 (2011).
140. Gateva V, Sandling JK, Hom G et al. A large-scale replication study identifies TNIP1, PRDM1, JAZF1, UHRF1BP1 and IL10 as risk loci for systemic lupus erythematosus. Nat. Genet. 41(11), 1228-1233 (2009).
141. Taylor KE, Chung SA, Graham RR et al. Risk alleles for systemic lupus erythematosus in a large case-control collection and associations with clinical subphenotypes. PLoS Genet. 7(2), E1001311 (2011).
142. Moser KL, Kelly JA, Lessard CJ, Harley JB. Recent insights into the genetic basis of systemic lupus erythematosus. Genes Immun. 10(5), 373-379 (2009).
143. James CM, Abdad MY, Mansfield JP et al. Differential activities of alpha/beta IFN subtypes against influenza virus in vivo and enhancement of specific immune responses in DNA vaccinated mice expressing haemagglutinin and nucleoprotein. Vaccine 25, 1856-1867 (2007).
144. Gibbert K, Dittmer U. Distinct antiviral activities of IFN-a subtypes. Immunotherapy 3(7), 813-816 (2011).
145. Virgin HW, Wherry EJ, Ahmed R. Redefining chronic viral infection. Cell 138(1), 30-50 (2009
146. Germaine RN, Meier-Schellersheim M, Nita-Lazar A, Fraser ID. Systems biology in immunology; a computational modelling perspective. Annu. Rev. Immunol. 29, 527-585 (2011).
147. Ge D, Fellay J, Thompson AJ et al. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature 461(7262), 399-401 (2009).
148. Thomas DL, Thio CL, Martin MP et al. Genetic variation in IL28B and spontaneous clearance of hepatitis C virus. Nature 461(7265), 798-801 (2009).
149. Tanaka Y, Nishida N, Sugiyama M et al. Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C. Nat. Genet. 41(10), 1105-1109 (2009).
150. Suppiah V, MoldoVan M, Ahlenstiel G et al. IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy. Nat. Genet. 41(10), 1100-1104 (2009).
151. Rauch A, Kutalik Z, Descombes P et al. Genetic variation in IL28B is associated with chronic hepatitis C and treatment failure: a genome-wide association study. Gastroenterology 138(4), 1338-1345 (2010).
152. Ahlenstiel G, Booth DR, George J. IL28B in hepatitis C virus infection: translating pharmacogenomics into clinical practice. J. Gastroenterol. 45(9), 903-910 (2010).
153. Arrnaud N, Dabo S, Akazawa D et al. Hepatitis C virus reveals a novel early control in acute immune response. PLoS Pathog. 7(10), E1002289 (2011).
154. Ramos EL. Preclinical and clinical development of pegylated interferon-lambda 1 in chronic hepatitis C. J. Interferon Cytokine Res. 30(8), 591-595 (2010).
155. Pfeffer LM. Biologic activities of natural and synthetic type I interferons. Semin. Oncol. 24(3 Suppl. 9), S9-63-S9-69 (1997).
156. Dubois A, Francois C, Descamps V et al. Enhanced anti-HCV activity of interferon alpha 17 subtype. Virol. J. 6, 70-80 (2009).
157. Dreyfus DH. Autoimmune disease: a role for new anti-viral therapies? Autoimmun. Rev. 11(2), 88-97 (2011).
158. Serafini B, Severa M, Columba-Cabezas S et al. Epstein-Barr virus latent infection and BAFF expression in B cells in the multiple sclerosis brain: implications for viral persistence and intrathecal B-cell activation. J. Neuropathol. Exp. Neurol. 69(7), 677-693 (2010).
159. Hesse D, Krakauer M, Lund H et al. Disease protection and interleukin-10 induction by endogenous interferon-b in multiple sclerosis. Eur. J. Immunol. 18(2), 1468-1331 (2011).
160. Barun B, Bar-Or A. Treatment of multiple sclerosis with anti-CD20 antibodies. Clin. Immunol. 142(1), 31-37 (2011).
161. Liao AP, Salajegheh M, Nazareno R et al. Interferon b is associated with type I interferon-inducible gene expression in dermatomyositis. Ann. Rhem. Dis. 70(5), 831-836 (2011).
162. Chen M, Chen G, Nie H et al. Regulatory effects of IFN-beta on production of osteopontin and IL-17 by CD4+ T cells in MS. Eur. J. Immunol. 39(9), 2525-2537 (2009).
163. Gerlach N, Gibbert K, Alter C et al. Anti-retroviral effects of type I interferon subtypes in vivo. Eur. J. Immunol. 39, 136-146 (2009).
164. Bayer W, Lietz R, Johrden L et al. Improved vaccine protection against retrovirus infection after coadministration of adenoviral vector encoding viral antigens and type I interferon subtypes. Retrovirology 8, 75-90 (2011)